Ms. Longstaff has over 15 years of health outcomes research experience. She has worked in the Technology Appraisals team at the National Institute for Health and Care Excellence (NICE), and in HTA and Market Access roles of escalating responsibility in Pfizer UK and Daiichi-Sankyo UK & Ireland.
Ms. Longstaff has extensive experience overseeing the development, adaptation and implementation of value propositions, market access initiatives, and data generation projects, spanning a wide range of therapeutic areas.
Prior to joining Maple Health Group, she was Vice President of Operations at Medlior Health Outcomes Research, having previously overseen Medlior’s HTA and Evidence Synthesis workstreams.
Ms. Longstaff attended the London School of Economics earning her Master of Sciences in International Health Policy. Prior to that, she attended the University of Calgary where she earned a Bachelor of Health Sciences in Health & Society.
